GlassScriptPhysician profile
Seth A Goldman
NPI 1417578303
$2,765.52
in general payments reported to CMS, 2019-2025
25 companies · $2,312 in 2025
The $2,312 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.66 · 2024: $434 · 2025: $2,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $568.75 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $528.97 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $473.05 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $259.78 | 2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $180.71 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.90 | 2024-2025 | Jardiance, Ofev, Jascayd |
| Sobi, INC | $124.99 | 2025 | |
| Abbvie INC. | $92.53 | 2025 | |
| Lundbeck LLC | $56.07 | 2025 | Rexulti |
| Ucb, INC. | $54.32 | 2024 | Nayzilam |
| Pfizer INC. | $31.93 | 2024-2025 | |
| Dynavax Technologies Corporation | $23.75 | 2024-2025 | Heplisav-B |
| Exact Sciences Corporation | $23.01 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $22.21 | 2025 | Evkeeza |
| Optinose US, INC. | $20.19 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2025 | Vpriv |
| Dexcom, INC. | $18.23 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.92 | 2024 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $17.63 | 2025 | Opsumit, Uptravi |
| Amneal Pharmaceuticals LLC | $17.49 | 2024 | Unithroid |
| Esperion Therapeutics, INC. | $16.67 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2025 | Zoryve |
| Gilead Sciences, INC. | $14.58 | 2025 | |
| Glaxosmithkline, LLC. | $14.20 | 2025 | Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.